Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
    • What are Neuroendocrine Cancers?
    • What are Pheos & Paras?
    • NET Symptoms
    • NET Types
    • Causes
    • Treatments
    • Grades
    • Diagnosis
    • Prognosis
    Consider the Grey Area
  • Patients & Carers
    • Patient & Carer Support
    • Patient Resources
    • Optimal Care Pathway
    • NET Nurse
    • Patient Stories
    • Share your Story
    • Australian NET Specialists
    • Clinical Trials
    • Living with NETS
    • Specialist Support Services
    Consider the Grey Area
  • Healthcare Professionals
    • Optimal Care Pathway
    • Professional Learning
    • Patient Referral
    • Clinical Trials
    • NET Symptoms
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order Booklets & Resources
    Consider the Grey Area
  • Get Involved
    • Advocate for Us
    • Share your Story
    • Donate
    • Fundraise
    • Events
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Volunteer
    Senate MailChimp
  • March4NETs
NET Nurse
Donate

Home » News » 12th INCA Global NET Cancer Advocate Summit

12th INCA Global NET Cancer Advocate Summit

  • September 17, 2024

The 12th INCA Global NET Cancer Advocate Summit was held in Segovia Spain 9 -10 September 2024. The Summit saw representatives from 25 member organisations from around the world and was attended by INCA Research Committee Chair and NeuroEndocrine Cancer Australia CEO, Meredith Cummins (pictured).

For each of the INCA Pillars there were member showcase presentations highlighting the “Best Practices and challenges” and then breakout groups to further discuss plans for INCA and address issues. The Awareness Pillar then had a session on Raising Awareness Globally  – Dr Rocio Garcia-Carbonero (ENETs Chair) spoke about “ Working in synergy with ENETs to improve Understanding of NETs”.

In the afternoon there was a Best Practices and challenges in working with the Medical Community. NECA was invited to present our HCP Education modules and deliver our successes and lessons learned.

On day 2 Best Practices and challenges in partnering in NET Research. NECA showcased the research it is involved in and also provide information about being included in research and working with Researchers and clinicians. 

After this Dr Thorvardur Halfdanarson (NANETs President) presented “Meaningful Involvement of Patients in NET Research”. The afternoon session discussed NET Cancer Day 2024. 

Following this the focus was on Best Practices and challenges in evidence based advocacy. The final 2 presentations were “Advocacy in the NEC Community” by Susan Meckler Plummer and “Data Collection and publication – a how to guide” by Prof John Ramage (Kings Health Partners NET Centre).

The Summit was a wonderful event for networking and collaborating, learning from and educating each other! Read the full INCA summary here

INCA Summit 2024 -Segovia, Spain
INCA Summit 2024 -Segovia, Spain
Break out session at INCA Summit 2024 -Segovia, Spain
INCA Summit 2024 -Segovia, Spain
INCA Summit 2024 -Segovia, Spain
Meredith Cummins (NECA CEO) at INCA Summit 2024 -Segovia, Spain
Meredith Cummins (NECA CEO) at INCA Summit 2024 -Segovia, Spain
INCA Summit 2024 -Segovia, Spain
Meredith Cummins (NECA CEO) at INCA Summit 2024 -Segovia, Spain
Meredith Cummins (NECA CEO) at INCA Summit 2024 -Segovia, Spain
Group photo, INCA Summit 2024 -Segovia, Spain

Share this post

Recent posts

VHL Awareness Month 2025

May 6, 2025

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

May 5, 2025

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

April 29, 2025

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

April 5, 2025
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousMedicines Australia PharmAus2024 event, Parliament House, Canberra
NextBiomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENsNext

Related Posts

VHL Awareness Month 2025

May is internationally recognised as Von Hippel-Lindau (VHL) Awareness Month—a time to highlight this rare genetic, and in some case not genetic, condition and the

NET Patient Chris, from Ballarat, Raises Awareness of Neuroendocrine Cancer

NeuroEndocrine Cancer Australia (NECA) is proud to recognise the advocacy efforts of NET patient Chris Geljon, who has taken the time to raise awareness of

Help Us Grow: Connect NECA with Corporate Partners to Make a Lasting Impact

NeuroEndocrine Cancer Australia (NECA) is proud to be the voice for thousands of Australians living with Neuroendocrine Cancer (NETs). But to do more — reach

Neuroendocrine Cancer Awareness Daily Mail 5 April 2025

Jo O’Halloran was in her early fifties when the symptoms she and her friends had heard so much about started to appear. ‘I was always

View All

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Patients & Carers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

Healthcare Professionals

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2025 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin